Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices.
Sanofi has launched its short-acting follow-on insulin lispro product, Admelog, referencing Eli Lilly’s Humalog. The rapid-acting human insulin analog is indicated to improve glycemic control in adults and children with diabetes and is available in both vials and in a pen (SoloStar) presentation.
Under Sanofi’s “Insulins VALyou Savings Program,” nonfederally insured patients will be eligible for a savings card that will allow them to purchase the product for a total out-of-pocket cost of $99 for a 10-mL vial or $149 for a box of five 3-mL pens for a period of 12 months. After the year is over, patients can re-register for the program. Sanofi says that the savings program will lower out-of-pocket costs for patients (including the uninsured or patients who are commercially insured under high-deductible plans) who would otherwise have to pay the full list price of $90 per 3-mL pen or $233 per 10-mL vial for Admelog.
Michelle Carnahan, head of North America diabetes and cardiovascular for Sanofi, said that the program will help patients to “…gain access to insulins they need to help manage their disease, at a clear and consistent price, regardless of their pharmacy choice."
Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices, and while these savings are modest in comparison to the historical price increases for insulin lispro—when the brand name Humalog first launched in 1996, it cost just $21 per vial—they do reflect a trend in launch prices for follow-on insulins. Basaglar, Boehringer Ingelheim’s insulin glargine follow-on, launched in 2016 at a 15% discount to the branded Lantus and Toujeo.
Admelog was first tentatively approved by the FDA in September 2017 based on its similarity to the originator insulin lispro, and it was then granted final approval in December 2017 after the conclusion of patent litigation with Eli Lilly concluded. In the United States, follow-on insulin products like Admelog are not regulated as biosimilars; because the FDA treats innovator insulins as drugs, rather than as biologic products, treatments such as Admelog are regulated as follow-ons.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.